Liraglutide reduces systolic blood pressure in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials.

Zhao D, Liu H, Dong P

Clinical and experimental hypertension (New York, N.Y. : 1993)15 Oct 2019Cited by 7 (Europe PMC)

PMID31610701DOI10.1080/10641963.2019.1676771PepBankPUB-31610701

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanSystematic reviewEfficacy outcome
In a meta-analysis of randomized trials in adults with type 2 diabetes, liraglutide 1.8 mg/day reduced systolic blood pressure versus placebo.
In plain wordsIn adults with type 2 diabetes, pooled trials show liraglutide 1.8 mg/day lowered systolic blood pressure compared with placebo.
Peptide
Liraglutide
Outcome
DecreaseSystolic blood pressure
Study
n: not reported in source
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
1.8 mg/day · 16 ± 9 weeks follow-upAs given in this study (human).
Measurements
Weighted mean difference, systolic blood pressure
−5.39 mm Hg
liraglutide 1.8 mg/day vs placebo
Source sentences
Summary
Liraglutide 1.8 mg/day reduced systolic blood pressure (weighted mean differences -5.39 (95% confidence interval, -7.26, -3.51) mm Hg, p < .001)
1 context sentence(design, population, supporting numbers)
Summary · context
Total 968 patients were included in 10 randomized, double-blind, placebo-controlled trials with a follow-up of 16 ± 9 weeks.
Report a problemFND-3161070101
02HumanSystematic reviewEfficacy outcome
In a meta-analysis of randomized trials in adults with type 2 diabetes, liraglutide 1.8 mg/day reduced body weight versus placebo.
In plain wordsIn adults with type 2 diabetes, pooled trials show liraglutide 1.8 mg/day lowered body weight compared with placebo.
Peptide
Liraglutide
Outcome
DecreaseBody weight
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
1.8 mg/day · 16 ± 9 weeks follow-upAs given in this study (human).
Measurements
Weighted mean difference, body weight
−2.07 kg
liraglutide 1.8 mg/day vs placebo
Source sentences
Summary
and body weight (weighted mean differences -2.07 (95% confidence interval, -2.62, -1.51) kg, p < .001) in patients with type 2 diabetes mellitus.
1 context sentence(design, population, supporting numbers)
Summary · context
Total 968 patients were included in 10 randomized, double-blind, placebo-controlled trials with a follow-up of 16 ± 9 weeks.
Report a problemFND-3161070102
03HumanSystematic reviewEfficacy outcome
In a meta-analysis of randomized trials in adults with type 2 diabetes, diastolic blood pressure did not differ significantly between liraglutide 1.8 mg/day and placebo.
In plain wordsIn adults with type 2 diabetes, pooled trials found no significant difference in diastolic blood pressure between liraglutide and placebo.
Peptide
Liraglutide
Outcome
No significant changeDiastolic blood pressure
Study
n: not reported in source
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
1.8 mg/day · 16 ± 9 weeks follow-upAs given in this study (human).
Measurements
Weighted mean difference, diastolic blood pressure
−0.53 mm Hg
liraglutide 1.8 mg/day vs placebo
Source sentences
Summary
There was no significant difference for changes of diastolic blood pressure between liraglutide 1.8 mg/day and placebo in these patients (weighted mean differences -0.53 (95% confidence interval, -1.96, 0.89) mm Hg, p > .05).
1 context sentence(design, population, supporting numbers)
Summary · context
Total 968 patients were included in 10 randomized, double-blind, placebo-controlled trials with a follow-up of 16 ± 9 weeks.
Report a problemFND-3161070103
04HumanSystematic reviewSafety outcome
In a meta-analysis of randomized trials in adults with type 2 diabetes, heart rate increased more with liraglutide 1.8 mg/day than with placebo.
In plain wordsIn adults with type 2 diabetes, pooled trials found heart rate rose more with liraglutide than with placebo.
Peptide
Liraglutide
Outcome
IncreaseHeart rate
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
1.8 mg/day · 16 ± 9 weeks follow-upAs given in this study (human).
Measurements
Weighted mean difference, heart rate
6.03 kg (as written in source)
liraglutide 1.8 mg/day vs placebo
Source sentences
Summary
The increases of heart rate were greater than placebo in patients treated with liraglutide 1.8 mg/day (weighted mean differences 6.03 (95% confidence interval, 4.78, 7.29) kg, p < .001).
1 context sentence(design, population, supporting numbers)
Summary · context
Total 968 patients were included in 10 randomized, double-blind, placebo-controlled trials with a follow-up of 16 ± 9 weeks.
Report a problemFND-3161070104
05HumanSystematic reviewMechanism
In a meta-analysis of randomized trials in adults with type 2 diabetes, systolic blood pressure reduction did not correlate significantly with weight loss under liraglutide 1.8 mg/day.
In plain wordsIn adults with type 2 diabetes, pooled trials found no significant link between blood pressure reduction and weight loss with liraglutide.
Peptide
Liraglutide
Outcome
No significant changeCorrelation between systolic blood pressure reduction and weight loss
Study
n: not reported in source
Outcome group
Blood pressure · Cardiovascular
Studied dose
1.8 mg/day · 16 ± 9 weeks follow-upAs given in this study (human).
Source sentences
Summary
There was no significant correlation between reduction of systolic blood pressure and weight loss in patients treated with liraglutide 1.8 mg/day (p = .24).
1 context sentence(design, population, supporting numbers)
Summary · context
Total 968 patients were included in 10 randomized, double-blind, placebo-controlled trials with a follow-up of 16 ± 9 weeks.
Report a problemFND-3161070105

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.